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Abstract Hemicrania continua (HC) is a unilateral and
continuous primary headache with superimposed exacer-
bations frequently associated with autonomic features.
Diagnostic criteria of HC, according to II Edition of
International Classification of Headache Disorders require
complete response to indomethacin. HC is probably mis-
diagnosed more often than other primary headaches. We
aim to analyze characteristics of a series of 22 consecutive
cases of HC. We recruited patients from a headache out-
patient clinic in a tertiary hospital over a 3-year period
(January 2008 to January 2011). We prospectively gathered
demographic and nosological characteristics and consid-
ered referral source and delay between onset of headache
and diagnosis of HC. Twenty-two patients (14 females,
8 males) out of 1,150, who attended the mentioned clinic
during the inclusion period (1.9 %) were diagnosed with
HC. All cases responded to indomethacin. No patient
received a diagnosis of HC before attending our headache
office. Mean latency of diagnosis was 86.1 ± 106.5 months
(range 3–360). 11 patients (50 %) were referred from pri-
mary care, with 9 (40.9 %) from other neurology clinics
and 2 (9.1 %) from other specialities offices. According to
our series, HC is not an infrequent diagnosis in a head-
ache outpatient clinic. Diagnostic delay is comparable to
data collected in previous studies. As HC is frequently
misdiagnosed, we thing there is a need for increasing
the understanding of this entity, potentially responsive to
indomethacin.
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Objectives
Hemicrania continua (HC) is a strictly unilateral continu-
ous headache of moderate intensity with superimposed
exacerbations often accompanied by autonomic symptoms,
and absolute response to indomethacin [1–3]. HC is an
uncommon primary headache disorder, so it may be mis-
diagnosed and mistreated. Therefore, there is a need for
increasing the understanding of this entity, potentially
responsive to indomethacin [4].
We aim to analyze demographic and nosological char-
acteristics of a series of 22 new cases of HC, including
reference source and latency of diagnosis.
Methods
We prospectively evaluated consecutive new patients with
HC attending a headache outpatient office in a tertiary
hospital over a 3-year period (January 2008 to January
2011). In every patient, we considered age at onset, sex,
background pain (side, site, type, intensity) and exacerba-
tion characteristics (frequency, intensity, periodicity, auto-
nomic symptoms). We collected referral source and delay
between onset of the headache and HC diagnosis. Secondary
headaches were excluded by magnetic resonance imaging
or computerized tomography scan where appropriate.
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21st Meeting of the European Neurological Society, May 2011,
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We assessed indomethacin response with a standard oral
trial up to 250 mg per day, during 10 days [5]. Therapeutic
results of patients in this series, including indomethacin side
effects and alternative therapies have been considered in
another article [6].
Results
During the inclusion period, we diagnosed 22 patients
(eight males, fourteen females) out of 1,150 (1.9 %), who
attended our headache clinic with HC. All of them fulfilled
ICHD-2 diagnostic criteria for HC, except the five patients
without autonomic symptoms who fulfilled alternative
Goadsby and Lipton criteria [7]. Mean age at onset was
41.8 ± 18.1 years (range 6–75) In all patients pain was
strictly unilateral, in 14 (63.6 %) right sided and in 8
(36.4 %) exclusively left sided. Temporal pattern was
always chronic and unremitting.
Background pain was generally rated as moderate
intensity (5.2 ± 1.2) and exacerbations were commonly
considered severe (8.4 ± 1.1) on a verbal analogical scale
(0: no pain, 10: the worst imaginable pain). In our series,
all patients suffered exacerbations and five (22.7 %) of
them did not have associated autonomic symptoms.
All our cases responded to a standard oral trial of
indomethacin, up to 250 mg per day [5]. Side effects were
documented in 13 patients (59.1 %), mainly dyspepsia and
dizziness. In these cases, we tried to reduce as far as pos-
sible indomethacin dose, to produce anesthetic blockade
when appropriate [6], or to change to another preventative
drug, mainly topiramate.
No patient had received a diagnosis of HC before
attending our headache clinic. Mean latency of diagnosis
was 86.1 ± 106.5 months (range 3–360). Eleven patients
(50 %) were referred from primary care, with 9 (40.9 %)
coming from other neurology clinics and 2 (9.1 %) from
others specialities offices. No patient had received indo-
methacin before referral to our headache clinic.
Discussion
HC was first designated by Sjaastad and Spierings [8] as a
unilateral headache strictly responsive to indomethacin.
Following this description, more than 100 cases of HC
have been reported in different countries [5]. In 2004, the
second Edition of International Classification of Headache
Disorders (ICHD-II) included HC within ‘‘Other Primary
Headache’’ group, and defined it as a strictly unilateral
continuous headache of moderate intensity, with periodic
exacerbations of variable duration and often accompanied
by autonomic symptoms [1]. Bilateral or shifting-side pain
localizations, or lack or enlarging of autonomic symptoms
accompanying pain exacerbations can be accepted when
diagnosing HC [5, 9] but, as in other series [5], we have not
considered non-indomethacin responders as HC, though
we will consider in the future to characterize patients with
non-absolute response to indomethacin [5]. Therefore, the
presence of one atypical feature, such as bilateral or
shifting sides localization, can be provisionally accepted
provided the rest of the features are typical.
HC is considered a predominantly female headache
[5, 7, 10] and mean age at symptoms onset is around
40 years [5, 7, 11, 12]. Regarding demographic charac-
teristics, our results are in line with previous reports.
Incidence and prevalence of HC is unknown. It was
initially considered as a quite infrequent syndrome, though
the increasing number of patients identified in headache
offices suggested that this headache syndrome may be
misdiagnosed and under recognized [4, 7, 10]. HC repre-
sents 1.9 % of headache patients attending our headache
clinic, data comparable to those obtained by Rossi et al. [4]
and in Vaga study of headache epidemiology [13].
Pain intensity in HC has been considered as mild to
moderate when considering background pain, though
reaching severe pain during exacerbations. According to
ICHD-II criteria [1], patients with HC are required to have
at least one cranial autonomic feature accompanying pain
exacerbations, although diagnosis of HC would be possible
without autonomic features when considering alternative
Goadsby and Lipton criteria [7]. As in other recent series
[5], a percentage of our patients did not associate auto-
nomic symptoms.
We would like to emphasize the need for a greater
awareness and understanding of HC. In a similar way as
described by Rossi et al. [4], none of our patients had
been diagnosed with HC and, so, they had not received
indomethacin before attending our headache clinic.
Latency between symptoms onset and diagnosis is larger
than should be expected for an entity potentially responsive
to treatment, but we found it comparable to Rossi et al.’s
results [4]. Some authors have provided data that could
help clinicians be more accurate in their diagnosis. Rossi
et al. reported patients’ experience on medications in their
case series—no patient who improved with triptans ended
up having HC, but many of those with a partial response to
NSAIDs or aspirin did. Cittadini et al. suggested that uni-
lateral photophobia helped to predict HC. We have not
found such predictive data in our series.
Conclusion
Hemicrania continua is not an infrequent diagnosis in our
headache outpatient clinic; burden of this entity is probably
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higher than observed. Diagnostic delay is high and com-
parable to data collected in previous studies. HC is fre-
quently misdiagnosed and there is a need for increasing the
understanding of this entity, which is potentially highly
disabling for patients who can achieve a pain-free state
when appropriately treated with indomethacin.
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